FDA Approves Genentech's Venclexta® Plus Acalabrutinib Combination Regimen for Previously Untreated Chronic Lymphocytic Leukemia

Core Viewpoint - The FDA has approved the combination of Venclexta® (venetoclax) and acalabrutinib for treating previously untreated adults with chronic lymphocytic leukemia (CLL), marking a significant advancement for newly diagnosed patients [1] Company Summary - Genentech, part of the Roche Group, announced the FDA approval based on the Phase III AMPLIFY study results [1]